国立研究開発法人国立がん研究センターは、日本の国立研究開発法人。国立高度専門医療研究センターの一つであり、日本におけるがん征圧の中核拠点として、がんその他の悪性新生物に対する診療、研究、技術開発、治験、調査、政策提言、人材育成、情報提供を行う。

During the past decade, National Cancer Center Hospital conducted 232 clinical trials. In the 10-year time frame, 232 clinical trials started and 92 clinical trials were completed, i.e. on average, 39.7% percent of trials that started reached the finish line to date. In the past 5 years, 124 clinical trials started and 66 clinical trials were completed. i.e. 53.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cancer Center Hospital" #1 sponsor was "Pfizer" with 44 trials, followed by "Eli Lilly and Company" with 19 trials sponsored, "Hoffmann-La Roche" with 19 trials sponsored, "Daiichi Sankyo Co., Ltd." with 15 trials sponsored and "Amgen" with 15 trials sponsored. Other sponsors include 187 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cancer Center Hospital" #1 collaborator was "AstraZeneca" with 15 trials as a collaborator, "Eli Lilly and Company" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 6 trials as a collaborator, "Ministry of Health, Labour and Welfare, Japan" with 6 trials as a collaborator and "Daiichi Sankyo Co., Ltd." with 5 trials as a collaborator. Other collaborators include 98 different institutions and companies that were collaborators in the rest 77 trials.

According to Clinical.Site data, the most researched conditions in "National Cancer Center Hospital" are "Breast Cancer" (14 trials), "Carcinoma, Non-Small-Cell Lung" (11 trials), "Gastric Cancer" (10 trials), "Solid Tumor" (10 trials) and "Lymphoma, Non-Hodgkin" (9 trials). Many other conditions were trialed in "National Cancer Center Hospital" in a lesser frequency.

Most popular intervention types in "National Cancer Center Hospital" are "Drug" (277 trials), "Biological" (20 trials), "Other" (20 trials), "Procedure" (8 trials) and "Radiation" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Carboplatin" (17 trials), "Paclitaxel" (17 trials), "Cisplatin" (14 trials) and "Gemcitabine" (14 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Center Hospital" are 273 trials for "All" genders and 29 trials for "Female" genders.

Currently, there are NaN active trials in "National Cancer Center Hospital". undefined are not yet recruiting, 82 are recruiting, 93 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 104 completed trials in National Cancer Center Hospital, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Center Hospital, 113 "Phase 1" clinical trials were conducted, 100 "Phase 2" clinical trials and 108 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".

National Cancer Center Hospital has several departments that took part in Clinical trials: "National Cancer Center Hospital" - 14 trials, "National Cancer Center Hospital East" - 290 trials, "National Cancer Center Hospital; Thoracic Medical Oncology" - 5 trials, "National Cancer Center Hospital East; Thoracic Oncology" - 4 trials, "National Cancer Center Hospital - Gastrointestinal Oncology" - 4 trials, "National Cancer Center Hospital; Gastrointestinal Oncology" - 2 trials, "National Cancer Center Hospital; Urology" - 2 trials, "National Cancer Center Hospital; Breast and Medical Oncology" - 2 trials, "National Cancer Center Hospital East; Breast and Medical Oncology" - 2 trials, "National Cancer Center Hospital; Hematology" - 2 trials, "National Cancer Center Hospital - Dept of Hepatobiliary and Pancreatic Oncology" - 2 trials